ALK Mutation

CI-VAR-00002677Explore in graph →CIViC 512

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
ALK Mutation	Ceritinib	Predictive	B	Supports Sensitivity Response	4	accepted	EID1237 In a phase 1 clinical trial (NCT01283516) 130 patients with advanced cancers all harboring ALK alterations were treated with ceritinib. Of 114 NSCLC patients treated with at least 400 mg/daily ceriti… (full text at CIViC) PMID 24670165 · Shaw et al., 2014 · Open in CIViC	civic
ALK Mutation	Lorlatinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11286 In this phase II, open-label, single-arm trial, 276 patients with a histologically or cytologically confirmed diagnosis of metastatic non-small-cell lung cancer that carried either an ALK or ROS1 gene… (full text at CIViC) PMID 30413378 · Solomon et al., 2018 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Neuroblastoma2
ALK Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID13288 In a Children's Oncology Group correlative study, 242 pretherapy tumours from patients enrolled on the phase III high-risk neuroblastoma trial ANBL0532 (NCT00567567) underwent ultra-deep targeted sequ… (full text at CIViC) PMID 40036726 · Berko et al., 2025 · Open in CIViC	civic
MYCN Amplification AND ALK Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	submitted	EID13291 In a Children's Oncology Group correlative study, 242 pretherapy tumours from patients enrolled on the phase III high-risk neuroblastoma trial ANBL0532 (NCT00567567) underwent ultra-deep targeted sequ… (full text at CIViC) PMID 40036726 · Berko et al., 2025 · Open in CIViC	civic